[HTML][HTML] Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic …
DJH Tan, CH Ng, SY Lin, XH Pan, P Tay… - The Lancet …, 2022 - thelancet.com
Background The clinical presentation and outcomes of non-alcoholic fatty liver disease
(NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular …
(NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular …
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
Antimicrobial resistance is a major public health problem globally. Likewise, forms of
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …
[图书][B] WHO consolidated guidelines on drug-resistant tuberculosis treatment
World Health Organization - 2019 - apps.who.int
Executive summary Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult
to treat than drug-susceptible ones, and threaten global progress towards the targets set by …
to treat than drug-susceptible ones, and threaten global progress towards the targets set by …
[HTML][HTML] Treatment of highly drug-resistant pulmonary tuberculosis
F Conradie, AH Diacon, N Ngubane… - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with highly drug-resistant forms of tuberculosis have limited treatment
options and historically have had poor outcomes. Methods In an open-label, single-group …
options and historically have had poor outcomes. Methods In an open-label, single-group …
[图书][B] WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment
World Health Organization - 2020 - books.google.com
BACKGROUND: Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult to
treat than drug-susceptible ones, and threaten global progress towards the targets set by the …
treat than drug-susceptible ones, and threaten global progress towards the targets set by the …
[HTML][HTML] MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention
and rehabilitation requires frequent update of existing guidelines. This review is aimed at …
and rehabilitation requires frequent update of existing guidelines. This review is aimed at …
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …
combination of multiple second-line drugs. These drugs are associated with numerous …
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial
KE Dooley, SL Rosenkranz, F Conradie… - The Lancet Infectious …, 2021 - thelancet.com
Background Bedaquiline and delamanid are the first drugs of new classes registered for
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …
Management of drug-resistant tuberculosis
Drug-resistant tuberculosis is a major public health concern in many countries. Over the past
decade, the number of patients infected with Mycobacterium tuberculosis resistant to the …
decade, the number of patients infected with Mycobacterium tuberculosis resistant to the …
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
S Borisov, E Danila, A Maryandyshev… - European …, 2019 - Eur Respiratory Soc
The World Health Organization (WHO) recommends that countries implement
pharmacovigilance and collect information on active drug safety monitoring (aDSM) and …
pharmacovigilance and collect information on active drug safety monitoring (aDSM) and …